Drug intelligence / Profile preview

Biokine WC

Development stage: Preclinical
Lead developer: Adamas Biotech
Administration: Topical

Overview

Biokine WC is a preclinical-stage nutraceutical developed by Adamas Biotech for wound care applications. The product is derived from green tea extracts, which are known for their antioxidant and anti-inflammatory properties. It is intended to support the physiological healing process of wounds by mitigating oxidative stress and inflammation at the injury site. As of 2024, the program remains in the preclinical phase of development.

Brand names: Biokine WC
Other names: Biokine Wound Care

Beyond the preview

Go deeper on Biokine WC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biokine WC.

Explore the full profile